CClinicalTrials.gg
CompletedNCT02959424Updated Aug 9, 2018

NEQOL Survey Spanish Validation in a Hispanic Clinic Based Population

An observational study in Gastroesophageal Reflux Disease and Esophageal Motility Disorders, sponsored by Carlos Robles-Medranda. Completed at 1 site in Ecuador. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by Carlos Robles-Medranda · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
385
Ages
18 Years and older
Sex
All
01

Study summary

Chronic esophageal disorders affect approximately one third part of global population, with a deleterious impact in the quality of life of patients. Measured of health related quality of life in chronic esophageal conditions such as gastroesophageal reflux disease and achalasia are widely used to measure this important patient-reported outcome. The Northwestern Esophageal Quality of Life (NEQOL) is a hybrid measure of esophageal illness, allowing for broad use across esophageal diseases while maintain sensitivity to nuances of a specific condition. The NEQOL is a reliable and valid hybrid measure of disease specific health related quality of life across several chronic esophageal conditions. The Ecuadorian Institute of Digestive Diseases aims to translate and validate this survey into Spanish for its use in a Hispanic population. This cross-sectional study aims to translate, apply and validate the NEQOL in the patients attending in the esophageal division of the institute.

Read the detailed description

Methods: An authorization for translating the survey into Spanish was obtained from the survey authors. The translation and cross-cultural adaptations were carried out based on guidelines and international criteria proposed by Sperber. The NEQOL was translated independently from English into Spanish by two professional translators. Each one provided a written report, which was combined by the authors in a new version that contained the most reliable translation for each question. The new version was back translated to English by two different professional translators, who were blinded to the original version of the NEQOL. A new English version was developed by combining the written reports. The aim of the back translation was to compare each item of the new English version with the original NEQOL. Each item of the new English version was compared with the original questionnaire by 30 native English speakers. The success of the translation was evaluated using two scales of comparison: comparability of language and similarity of interpretability. Each one used Likert scales ranging from 1 (extremely comparable/ extremely similar) to 7 (not at all comparable/ not at all similar). A mean score for each question was obtained. Questions with mean scores of three or less were included in the Spanish version. The Spanish version of the NEQOL was tested on 10 subjects diagnosed with GERD, each subject provided feedback on the survey content, which was used to make final corrections. The questionnaire contains fourteen questions; every statement refers to the impact of the esophageal condition in the quality of life. There are five options ranking from not at all true to very true, with every option meaning a numerical value, a higher grade in the questionnaire will express a better quality of life and a low impact in the health-related quality of life.

Patients above 18 years old with chronic esophageal disorders, that require a functional esophageal test such as ph-impedanciometry and/or high-resolution manometry, will be included. Written informed consent will be obtained. All participants will complete the questionnaire before performing the functional esophageal tests and a gastroenterologist specialized on functional esophageal pathology will perform the esophageal tests and analyze the results. Finally, the data from the questionnaire will be compared with the esophageal tests results in order to stablish if there is a correlation between the impact in the quality of life measured by the questionnaire and the tests results.

Statistical analysis: Base line characteristics will be analyzed using Chi-square o Fisher Test for categorical variable, and the Mann-Whitney Test for continuing variables. Continuous variables will be expressed as mean +/- standard deviation. The sensitivity, specificity, predictive values and accuracy will be calculated with the 95% Confidence Interval (95% CI). A P value of less than 0.05 was considered to be statistically significant. All the statistical analysis was performed using SPSS software suite v.22.

02

Conditions studied

  • Gastroesophageal Reflux Disease and Esophageal Motility Disorders
03

In context

Gastroesophageal Reflux

1,067 studies on the registry are indexed under Gastroesophageal Reflux; 188 are open to participants now.

This study's enrollment of 385 is above the median of 180 across 298 observational studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

This is the only study on the registry with Carlos Robles-Medranda as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hispanic patients above 18 years old with chronic esophageal disorders, that require a functional esophageal test such as ph-impedanciometry and/or high-resolution manometry

Inclusion criteria

  • Written informed consent obtained
  • Ability to complete the survey
  • Hispanic patients above 18 years old with chronic esophageal disorders, that require a functional esophageal test such as ph-impedanciometry and/or high-resolution manometry

Exclusion criteria

Exclusion Criteria:

  • Not able to complete the survey
  • Not in the range of age acceptable for inclusion
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
385 participants (actual)
Patient registry
No

Interventions

  • OtherSpanish Northwestern Esophageal Quality of Life questionnaire

    Also known as: Spanish NEQOL

06

What researchers measure

Primary outcomes

  1. To measure the disease related quality of life and its impact among patients with chronic esophageal disorders by translating and validating into Spanish the Northwestern Esophageal Quality of Life Scale survey.

    Time frame: 9 month

07

Study locations

1 site
  • Ecuadorian Institute of Digestive Diseases, Omnihospital
    Guayaquil, Guayas 090505, Ecuador
08

References and documents

Publications

  • El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871-80. doi: 10.1136/gutjnl-2012-304269. Epub 2013 Jul 13. PubMed 23853213 ↗
  • O'Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2013 Sep 21;19(35):5806-12. doi: 10.3748/wjg.v19.i35.5806. PubMed 24124325 ↗
  • Bedell A, Taft TH, Keefer L, Pandolfino J. Development of the Northwestern Esophageal Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. Am J Gastroenterol. 2016 Apr;111(4):493-9. doi: 10.1038/ajg.2016.20. Epub 2016 Feb 16. PubMed 26881974 ↗
  • Roman S, Gyawali CP, Xiao Y, Pandolfino JE, Kahrilas PJ. The Chicago classification of motility disorders: an update. Gastrointest Endosc Clin N Am. 2014 Oct;24(4):545-61. doi: 10.1016/j.giec.2014.07.001. Epub 2014 Aug 1. PubMed 25216902 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02959424
Lead sponsor
Carlos Robles-Medranda
Responsible party
Carlos Robles-Medranda (MD, Instituto Ecuatoriano de Enfermedades Digestivas) — Sponsor-investigator
First posted
Nov 9, 2016
Start date
Oct 2016
Primary completion
Oct 2017
Completion
Nov 2017
Last update
Aug 9, 2018

Study contacts

Carlos A Robles-Medranda, MD
principal investigator · Ecuadorian Institute of Digestive Diseases

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion